Forty Seven

Forty Seven Overview

Founded 2014
Founded
Status Private
Employees 68
Employees
Latest Deal Type M&A
Latest Deal Amount $4.9B
Latest Deal Amount

Forty Seven General Information

Description

Forty Seven Inc is a clinical-stage immuno-oncology company. It is engaged in developing novel checkpoint therapies to activate macrophages and help the patients in their fight against cancer. It founded that blocking CD47, a key signaling molecule that is overexpressed on cancer cells renders tumors susceptible to macrophages. It is also preparing investigational compounds into clinical testing. FSI-174, an anti-cKIT antibody, is being developed in combination with magrolimab as a novel, all-antibody conditioning regimen to address the limitations of current stem cell transplantation conditioning regimens. FSI-189, an anti-SIRP-alpha antibody, is being developed for the treatment of cancer, and certain non-oncology conditions, including transplantation conditioning.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Primary Office
  • 1490 O'Brien Drive
  • Suite A
  • Menlo Park, CA 94025
  • United States
+1 (650) 000-0000

Forty Seven Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Forty Seven Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 07-Apr-2020 $4.9B 00000 00.00 Completed Generating Revenue/Not Profitable
7. Secondary Transaction - Open Market 00000 Completed Clinical Trials - Phase 1
6. Secondary Transaction - Open Market 00000 Completed Clinical Trials - Phase 1
5. PIPE 07-Aug-2019 000 00000 Completed Clinical Trials - Phase 1
4. IPO 28-Jun-2018 00000 00000 00000 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series B) 17-Oct-2017 0000 00000 00000 Completed Clinical Trials - Phase 1
2. Grant 05-Apr-2017 $14.2M $74.8M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 01-Mar-2016 $74.8M $74.8M 00000 Completed Startup

Forty Seven Cap Table

To view Forty Seven‘s complete cap table, request access >>
Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 000
Series A2 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A1 34,400,000 $0.000100 8% $1 $1 1x $1 17.55%

Forty Seven Competitors (30)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
Avrobio Formerly VC-backed Cambridge, MA 000 00000 000000 - 000 00000
0000 000000 Formerly VC-backed Santa Monica, CA 000 00000 000000&0 00000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
00000000 Corporate Backed or Acquired Planegg, Germany 000 00000 000000000 00000
00000000 Formerly VC-backed London, United Kingdom 000 00000 000000000 00000

Forty Seven Executive Team (11)

Name Title Board Seat Contact Info
Mark McCamish Ph.D President, Chief Executive Officer & Board Member
Ann Rhoads Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Irv Weissman MD Co-Founder & Board of Director
Norman Kruse JD Chief Patent Counsel
Craig Gibbs Ph.D Executive

2 Former Executives

Forty Seven Board Members (8)

To view Forty Seven‘s full board member team, request access >>
Name Representing Role Since
Dennis Henner Ph.D Blackstone Life Sciences Board Member 000 0000
Ian Clark Forty Seven Board Member 000 0000
Jeffrey Bird Ph.D Sutter Hill Ventures Board Member 000 0000
Kristine Ball Forty Seven Board Member & Chairman of the Audit Committee 000 0000
Mark McCamish Ph.D Forty Seven President, Chief Executive Officer & Board Member 000 0000

2 Former Board Members

Forty Seven Investments (1)

To view Forty Seven‘s complete investment and acquisition history, request access >>
Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 0000000000 ( 01-Jun-2018 000000000 00000 00 Pharmaceuticals

Ready to get started?

Request a free trial